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Profita M, Sala A, Bonanno A, Riccobono L, Ferraro M, La
Grutta S, Albano GD, Montalbano AM, Gjomarkaj M. Chronic
obstructive pulmonary disease and neutrophil infiltration: role of
cigarette smoke and cyclooxygenase products. Am J Physiol Lung
Cell Mol Physiol 298: L261–L269, 2010. First published November 6,
2009; doi:10.1152/ajplung.90593.2008.—Cigarette smoke is the main
cause of chronic obstructive pulmonary disease (COPD), where it can
contribute to the observed airway inflammation. PGE2 is produced
within human airways, and both pro- and anti-inflammatory activities
have been reported. We quantitated PGE2 concentrations in induced
sputum supernatants from different groups of subjects and correlated
the obtained values to neutrophil infiltration as well as to the expres-
sion of cyclooxygenase-2 (COX-2). Cigarette smoke extract (CSE)
was used to evaluate the effect of smoking on COX-2 and PGE2
receptor expression as well as on PGE2 release in neutrophils and
alveolar macrophages (AM) obtained from normal donors. The effects
of PGE2 and of PGE receptor agonists and antagonists were evaluated
on the adhesion of neutrophil to a human bronchial epithelial cell line
(16HBE). PGE2 levels, COX-2 expression, and neutrophil infiltration
were significantly higher in normal smokers and COPD smokers (P
0.0001) compared with controls and COPD former smokers. Induced
sputum supernatant caused neutrophil adhesion to 16HBE that was
significantly reduced, in COPD smokers only, by PGE2 immunopre-
cipitation. In vitro experiments confirmed that CSE increased PGE2
release and COX-2 and PGE2 receptor expression in neutrophils and
AM; PGE2 enhanced the adhesion of neutrophils to 16HBE, and a
specific E-prostanoid 4 (EP4) receptor antagonist blunted its effect.
These results suggest that CSE promote the induction of COX-2 and
contributes to the proinflammatory effects of PGE2 in the airways of
COPD subjects.
alveolar macrophages; neutrophils; cigarette smoke extract; cycloox-
ygenase-2
CHRONIC OBSTRUCTIVE PULMONARY disease (COPD) is character-
ized by a progressive and irreversible airflow obstruction as a
result of a chronic inflammatory status of the airways.
Neutrophil accumulation in the lung is a prominent feature
of COPD, and an important role is played by neutrophil
chemoattractants being produced within the airways and/or by
the increase in neutrophil adhesion molecules expression (41).
The activation of resident alveolar macrophages (AM) by
different factors may be involved in the release of neutrophil
chemoattractants and plays a role in the recruitment of neutro-
phils into the airways (37).
Cigarette smoke is a major risk factor for a number of
diseases, including cancer, cardiovascular diseases, and COPD.
Cigarette smoke can cause the formation and release of differ-
ent inflammatory factors such as IL-8 (16), and it can increase
the expression of the adhesion molecules MAC-1 and LFA-1
on peripheral blood neutrophils (10), suggesting a potential
causative link between smoking, neutrophil recruitment, and
adhesion within the airways of COPD subjects.
Among the mediators involved in the development of airway
diseases, an important role is played by arachidonic acid (AA)
metabolites such as cyclooxygenase (COX) and lipoxygenase
metabolites (40). However, although the 5-lipoxygenase-de-
rived leukotrienes are known to be involved through the
interaction with their CysLT1 receptor in asthma and allergic
rhinitis (3), little attention has been paid, so far, to the potential
involvement of COX metabolites, namely PG, in airway dis-
eases.
The synthesis of PGE2, the main inflammatory PG, takes
place in several different cellular types within the airways,
including epithelial cells, follicular dendritic cells, fibroblasts,
and monocytes (36), but AM certainly represent a major source
of PGE2, in particular following LPS and granulocyte/macro-
phage colony-stimulating factor (GM-CSF)-dependent expres-
sion of the inducible form of COX, namely COX-2 (9). COX-2
expression is increased at the sites of inflammation, and its
enhanced expression has been reported in airway cells from
patients with COPD (36). Interestingly, increased PGE2 con-
centration in the exhaled breath condensate of patients with
COPD has also been reported (18).
In this study, we evaluated the concentrations of PGE2 in the
induced sputum obtained from COPD (smokers and former
smokers), healthy smoker, and control subjects. In light of the
results obtained and, in particular, of the apparent correlation
between PGE2 concentrations and neutrophil infiltration, we
tested the role of PGE2 in the recruitment of neutrophil and the
effect of cigarette smoke on COX-2 and E-prostanoid (EP)
receptors expression.
MATERIALS AND METHODS
Patients. We recruited four groups of subjects: COPD smokers
(n  12) and former smokers (n  24), asymptomatic smokers with
normal lung function (n  12), and healthy asymptomatic nonsmok-
ing subjects with normal lung function (n  15).
COPD subjects were defined and classified according to the criteria
reported by Global Initiative for Chronic Obstructive Lung Disease
(GOLD) guidelines (23) and were classified as stage1. Patients with
COPD and healthy smokers had a smoking history of 10 pack-year or
more. COPD former smokers patients had quit smoking for at least 2
yr. Reversibility test to bronchodilator was performed to exclude an
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asthmatic component, and the increase in forced expiratory volume in
1 s (FEV1) after salbutamol was lower than 12% and 200 ml,
compared with basal values, in all COPD subjects. All COPD subjects
were under treatment with long-acting -adrenergic agonists (salme-
terol 50-g bid).
All patients were characterized with respect to sex, age, smoking
history, COPD symptoms, comorbidity, and current history of treat-
ment. Exclusion criteria included the following: other systemic dis-
eases; other lung diseases apart from COPD and lung tumors; upper
respiratory tract infections; and treatment with glucocorticoids or
anticholinergics within the 3 mo before the study. None of the subjects
had received a prior or concomitant treatment with COX-2 inhibitors.
The local ethics committee approved the study, and participating
subjects gave their informed consent.
Sputum induction and processing. Sputum induction and process-
ing were performed according to the methods of Hargreave et al. (8)
with minor modifications. Briefly, patients in a fasting condition were
exposed for 20 min to an aerosol of 3% hypertonic saline solution
early in the morning, and sputum was collected into previously
weighted 50-ml sterile ampoules. The volume of the induced sputum
was previously determined, and an equal volume of DTT (0.1% in
saline; Sigma, St. Louis, MO) was added. After homogenization,
sputum samples were centrifuged at 800 g for 10 min to separate the
supernatants from the cell pellet. The supernatants were then aspirated
and frozen at 20°C in separate aliquots for the subsequent biochem-
ical analysis. The cells obtained from induced sputum were then
cytocentrifuged (Cytospin 2; Shandon, Runcorn, United Kingdom)
and stained with May-Grunwald-Giemsa. The slides were read blindly
by 2 independent investigators who counted at least 400 cells per
slide. The number of squamous cells was subtracted from the total cell
count to get the corrected cell number. The cytospins for immunocyto-
chemistry were prepared on 3-aminopropyltriethoxysilane (APTEX)-
coated slides by adding 100 l of cell suspension (5  105 cells/ml)
into Shandon II cytocentrifuge cups and centrifuging at 180 g for 5
min. The air-dry slides were fixed in paraformaldehyde-lysine-perio-
date (PLP) for 30 min and in 15% sucrose in Dulbecco’s PBS for 30
min. The slides were stored at80°C until use for immunocytochem-
ical staining.
Analysis of prostanoids in induced sputum supernatant. The ali-
quots from the supernatants recovered from induced sputum samples
were thawed, and PGE2 was extracted according to Powell (24). The
recovery was evaluated by using standard PGE2 (1 ng), which was
added to separate aliquots of induced sputum samples prepared and
extracted in parallel to the original samples. PGE2 concentrations
were evaluated using a commercially available radioimmunoassay
(RIA; Amersham International, Little Chalfont, Buckinghamshire,
United Kingdom). DTT was not retained during the solid phase
extraction, as verified using its rapid colorimetric reaction with the
Ellman reagent, and therefore its presence in the sputum samples did
not affect the quantitation of PGE2. Results are expressed as pico-
grams per milliliter induced sputum supernatant.
Immunocytochemistry. After thawing, immunostaining of COX-2
on sputum cells was performed using a mouse monoclonal anti-
COX-2 (IgG1) antibody (Cayman Chemical, Ann Arbor, MI) as
previously described (25). The cell identification was based on cell
morphology under light microscopy (400 final magnification), care-
fully referring to the cell type distribution in corresponding Diff-Quik-
stained slides; red staining identified positive cells. Two independent
observers counted a minimum of 600 cells, and the mean value of the
2 observations was used (r  0.93). The results were expressed as
percentage of positively staining cells over the total cell number.
Preparation of cigarette smoke extract. Cigarette smoke solution
was prepared as described previously (33) with some modifications.
Each commercial cigarette (Marlboro) was smoked for 5 min, and two
cigarettes were used per 25 ml of PBS to generate a cigarette smoke
extract (CSE)-PBS solution. The CSE solution was filtered through a
0.22-m pore sieve to remove bacteria and large particles. The smoke
solution was then adjusted to pH 7.4 and used within 30 min of
preparation. This solution was considered to be 100% CSE and diluted
to obtain the desired concentration in each experiment. The concen-
tration of CSE was calculated spectrophotometrically measuring the
optical density as previously described (12). The pattern of absor-
bance, among different batches, showed very little differences.
Stimulation of AM from bronchoalveolar lavage and neutrophils
from peripheral blood. AM were collected from the airways of
subjects with no pulmonary and systemic inflammatory diseases who
underwent bronchoscopy and bronchoalveolar lavage (BAL) for sus-
pected lung cancer and who finally resulted cancer free. Briefly, the
BAL was carried out in one of the subsegmental bronchi of the middle
lobe by injection of several aliquots of sterile saline (up to a total
volume of 0.2 l) reaspirated by gentle syringe suction. Immediately
after lavage, mucus was removed from the fluid by filtration through
a gauze, then BAL fluid was centrifuged at 400 g for 10 min at 4°C,
and cells were resuspended in RPMI. The BAL cytology was con-
ducted on cytocentrifuged slides (Cytospin; Shandon) stained by
May-Grunwald-Giemsa, and macrophages were separated by adhe-
sion.
Peripheral blood polymorphonuclear leukocytes were prepared
from healthy subjects with the use of dextran sedimentation and
centrifugation over Ficoll cushions, as previously described (26). AM
and neutrophils were treated with CSE (10%) for different time of
incubation (from 0 to 24 h) and added with calcium ionophore
A23187 (2.5 M; Sigma), and PGE2 production was evaluated as
described above. Expression of COX-1 and COX-2 isoforms was
performed by Western blot on cellular lysates as described below.
Furthermore, the expression of EP1, EP2, EP3, and EP4 receptors was
evaluated in neutrophils treated with the CSE (10%).
Western blot analysis. Total protein extracts from AM and neutro-
phils treated with CSE (10%) were resuspended in 2 Laemmli
buffer and separated by SDS-PAGE on 4–12% gradient gels followed
by electroblotting onto nitrocellulose membranes. The following an-
tibodies were used: mouse monoclonal anti-human COX-1 and
Table 1. Patients’ characteristics














Subject, n 15 12 24 12
Sex, male/female 9/6 7/5 14/10 6/6
Mean age, yr 62 (49–72) 59.4 (45–70) 65 (59–71) 70 (63–72) NS NS NS NS NS NS
FEV1, % predicted 100 (99–106) 97 (92–106) 64 (57–78) 60 (45–71) NS 0.0001 0.0001 0.0001 0.0001 NS
FEV1/FVC, % 98 (96–102) 94 (91–100) 71 (66–82) 69 (63–76) NS 0.001 0.001 0.001 0.001 NS
Pack years 0 54.3 (26.2–30) 0 65 (42–55) 0.0001 NS 0.0001 0.0001 NS 0.0001
Results are expressed as medians (25th to 75th percentiles). Statistical analysis was performed by Mann-Whitney. NS, not significant; S, smoker; fS, former
smoker; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity.
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COX-2 antibodies (Cayman Chemical) and rabbit polyclonal anti-
human EP1, EP2, EP3, and EP4 receptor antibodies (Cayman Chem-
ical). Primary antisera were visualized with horseradish peroxidase-
conjugated secondary antibody (Sigma) and developed with an enhanced
chemiluminescence system (Amersham International). Approximate mo-
lecular masses were determined using calibrated prestained standards
(Amersham International). Negative controls were performed in the
absence of primary antibody or including an isotype control antibody.
-Actin (Sigma) was used to normalize the amount of protein in-
cluded in the Western blot analysis.
Real-time quantitative RT-PCR of muscarinic EP1, EP2, EP3, and
EP4 receptors. Total cellular RNA was extracted from cells according to
the method of Chomczynski and Sacchi using the RNAzol kit (Biotec
Italia, Rome, Italy). Total RNA (4 g) was reverse-transcribed into
cDNA using Moloney murine leukemia virus (MMLV)-RT and oli-
go(dT)12–18 primers (Invitrogen) in a 25-l reaction mixture. Real-time
quantitative PCR of EP1, EP2, EP3, and EP4 receptor subtypes of human
PGE2 receptors was carried out using the ABI PRISM 7900HT Sequence
Detection System (Applied Biosystems) using specific FAM-labeled
probes and primers (TaqMan Assays on Demand; Applied Biosystems).
GAPDH gene expression was used as endogenous control. Gene expres-
sion levels were expressed as threshold cycle crossover points (30).
Adhesion assay. Purified peripheral blood neutrophils were resus-
pended in PBS (106 cells/ml), labeled for 45 min at 37°C with 50
g/ml fluorochromic dye SFDA (Molecular Probes), washed, and
resuspended in PBS (0.4  106 cells/ml). Neutrophil adhesion was
performed according to Zeidler et al. (44) with minor modifications.
The simian virus 40 (SV40) large T antigen-transformed human
airway epithelial cell line (16HBE) was used for adhesion assay of
neutrophils. 16HBE cell line was cultured as adherent monolayers in
MEM supplemented with 10% heat-inactivated (56°C, 30 min) fetal
calf serum  100 U/ml penicillin and 100 mg/ml streptomycin.
16HBE cells have previously been used to study the functional
properties of bronchial epithelial cells in inflammation (15). Immedi-
ately before addition of neutrophils, medium was removed from
16HBE cultures (70,000 cells/well) grown to confluence in standard
24-well culture plates, and cells were washed with warm PBS.
Labeled neutrophils (0.2  106 cells/well) were added in a final
volume of 0.5 ml. The plates were incubated at 37°C for 25 min, and
total fluorescence was evaluated using an excitation wavelength of
485 nm and monitoring emission at 530 nm in a Wallac 1420 Victor
multilabel counter (PerkinElmer). Subsequently, nonadherent cells
were removed by washing, and fluorescence was measured to evaluate
bound cells. Adhesion was expressed as percentage of the fluores-
cence ratio of bound cells to total cells. All test points were performed
in triplicate.
Effect of induced sputum supernatant and PGE2 on neutrophil
adhesion. The induced sputum supernatants (1 ml) were added to
neutrophils for 18 h. At the end of the incubation time, the neutrophils
were centrifuged at 1,000 rpm for 10 min, and adhesion was assessed
as described above. To determine the contribution of PGE2 present in
induced sputum supernatants to the observed effect on neutrophil
adhesion, selected samples (6 COPD smokers and 6 COPD former
smokers) were incubated in the presence or absence of PGE2 affinity
Fig. 1. PGE2 concentrations and cyclooxygenase-2 (COX-2) expression in induced sputum samples. A: PGE2 concentrations in supernatants of induced sputum
samples obtained from controls, healthy smokers, chronic obstructive pulmonary disease (COPD) former smokers, and COPD smoker subjects. Samples were
analyzed by specific radioimmunoassay (RIA) kits as described in MATERIALS AND METHODS. B: percentage of COX-2-expressing cells over the total number of
cells obtained from induced sputum samples. Cells obtained from induced sputum samples of controls, healthy smokers, and COPD former smoker and COPD
smoker subjects were immunostained using a COX-2-selective monoclonal antibody as described in MATERIALS AND METHODS. Data are expressed as medians
and 25th to 75th percentiles (boxed) of PGE2 concentrations or percentage of COX-2-positive cells. Minimum and maximum values are represented by error bars.
Statistical analysis was performed by Kruskal-Wallis test and Dunn procedure.
Table 2. Total and differential cell count from induced sputum samples














Macrophages (104) 120.6 (52–147.7) 233.3 (147–330) 59.9 (28.1–167) 66.5 (56–93.6) 0.01 NS NS 0.004 0.003 NS
Neutrophils (104) 26.5 (7.3–43) 106.4 (51–255) 159 (72–413) 491 (241–783) 0.02 0.001 0.0001 NS 0.02 0.055
Lymphocytes (104) 0 (0–1.8) 2.6 (0–5.5) 0.06 (0–4.6) 0 (0–2.7) NS NS NS NS NS NS
Eosinophils (104) 0 (0–0) 1.6 (0–4.61) 1.2 (0–12.2) 5.0 (0.1–10.9) NS 0.02 0.02 NS NS NS
Epithelial cells (104) 0 (0–3.0) 0 (0–2.4) 2.0 (0–7.0) 0 (0–4.0) NS NS NS NS NS NS
Total cells (106) 1.5 (0.6–2.2) 3.7 (2.4–5.6) 2.6 (1.1–6.9) 5.7 (3.1–8.6) 0.01 0.05 0.05 NS NS NS
Results are expressed as medians (25th to 75th percentiles). Statistical analysis was performed by Mann-Whitney.
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sorbent (mouse anti-PGE2 IgG covalently bound to Sepharose 4B;
Cayman Chemical) as previously described (25).
The adhesion of neutrophils to 16HBE, with or without pretreat-
ment with CSE (10%), was also tested on treatment of neutrophils
with synthetic PGE2 (Sigma) at different concentrations, the EP2
receptor agonist Butaprost (Cayman Chemical), the specific EP4
receptor antagonist AH-23848 (30 M; Cayman Chemical), the po-
tent and specific TxA2-PGH2 (TP) receptor antagonist GR-32191B
(100 nM; Cayman Chemical), and PGE2 (10 nM) in the presence of
AH-23848 or GR-32191B. Controls were carried out incubating the
neutrophils with the appropriate dilution of the solvent used for the
tested compounds (DMSO).
Statistical analysis. The data relative to induced sputum are ex-
pressed as medians and 25th to 75th percentiles. Statistical analysis
was performed using the nonparametric Mann-Whitney U test for
comparison between groups. The Spearman rank test was used for
correlation between data. A value of P  0.05 was accepted as
statistically significant. The results obtained from recovery experi-
ments are expressed as means and SD or SE of n replication. The
results of in vitro experiments were analyzed using ANOVA with
Fisher test correction or t-test.
RESULTS
Patients and differential cell counts. As expected, pulmo-
nary functions significantly decreased in COPD subjects
(smokers or former smokers) compared with either control
subjects or healthy smokers (Table 1).
In line with published data, the results of the differential cell
counts performed on induced sputum samples showed a statis-
tically significant increase in the number of cells both in
healthy smokers and COPD subjects (either smokers or former
smokers). In healthy smokers, this increase reflected an in-
crease in the number of both macrophages and neutrophils,
whereas in COPD subjects neutrophils showed a large increase
(in particular in actual smokers) with the number of macro-
phages being significantly lower than healthy smokers and
similar to normal controls (Table 2). In agreement with previ-
ous reports, eosinophils also resulted significantly higher in
COPD subjects compared with controls (28), whereas lympho-
cytes did not show significant changes (11, 20, 28), possibly
reflecting the relatively different sampling of the airways
(bronchial vs. alveolar) obtained with the induced sputum
compared with BAL.
PGE2 and COX-2 expression in induced sputum samples.
The recovery of PGE2, as assessed in induced sputum samples
analyzed with and without the addition of 1 ng of synthetic
PGE2, was 89 	 10%. PGE2 concentrations in supernatants of
induced sputum samples obtained from COPD smokers were
significantly higher than those observed in COPD former
Fig. 2. Correlation between PGE2 and neutrophil concentrations in the super-
natants of induced sputum samples obtained from either current (F) or former
(‚) smoker COPD subjects. Statistical analysis was performed using the
Spearman rank test.
Fig. 3. Adhesion of neutrophils in the presence of supernatant from induced
sputum samples. Neutrophils obtained from peripheral blood were incubated
with the supernatant (1 ml) of induced sputum samples obtained from COPD
smokers and COPD former smokers. Supernatant was used as obtained from
induced sputum processing or after depletion of PGE2 by immunoprecipitation
with a specific affinity sorbent (mouse monoclonal anti-PGE2 antibody cou-
pled to Sepharose 4B). Adhesion was assessed by fluorescence measurements
using a Wallac 1420 Victor multilabel counter (PerkinElmer) as described in
MATERIALS AND METHODS. Results are expressed as means 	 SD of percentage
of fluorescence. Statistical analysis was performed using ANOVA with Fisher
protected least significant differences correction for multiple comparisons.
*P  0.05 vs. induced sputum.
Table 3. COX-2 expression by different cell types in induced sputum samples














Macrophages, % 2.5 (2–3.2) 13.9 (11.1–15.8) 12.2 (9.1–15.3) 29.2 (28.3–35) 0.0001 0.0004 0.0002 NS 0.0002 0.0004
Neutrophils, % 1.0 (0–1.2) 6.0 (3–11.3) 6.0 (2.9–6.4) 12.3 (6.9–14.3) 0.0001 0.0004 0.0002 NS 0.05 0.005
Lymphocytes, % 0 (0–0) 0 (0–0) 0 (0–0) 0 (0–0) NS NS NS NS NS NS
Eosinophils, % 0 (0–0) 0 (0–0.2) 0 (0–0) 0 (0–0) NS NS NS NS NS NS
Epithelial cells, % 0 (0–0) 0 (0–0) 0 (0–0) 0 (0–0) NS NS NS NS NS NS
Total cells 3.8 (2.3–4.2) 21.6 (13.3–25.6) 17.4 (15.2–20) 46.0 (36.9–49.5) 0.0001 0.0004 0.0002 NS 0.0005 0.0004
PGE2, ng/ml 0.3 (0.2–0.4) 1.3 (0.8–3.1) 0.6 (0.3–1.3) 3.2 (1.5–4.4) 0.004 0.002 0.0001 0.05 0.05 0.0001
Results are expressed as medians (25th to 75th percentiles). COX-2, cyclooxygenase-2.
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smokers, healthy smokers, and control subjects (P  0.0001,
P  0.0005, and P  0.0011, respectively); interestingly,
healthy smokers also showed values higher than control sub-
jects (Fig. 1A).
The percentage of total COX-2-positive cells recovered from
induced sputum samples increased in COPD smokers com-
pared with COPD former smokers, healthy smokers, and con-
trol subjects (P  0.0004, P  0.0005, and P  0.0002,
respectively; Fig. 1B); again, healthy smokers and COPD
former smokers showed a higher number of COX-2-staining
cells compared with controls. Macrophages and neutrophils
represented the main cell types expressing COX-2 in all groups
of subjects (Table 3).
In COPD nonsmokers, the correlation between PGE2 and
neutrophils has a 
 of 0.42 and is statistically significant (P 
0.05), whereas the same correlation in COPD smokers (with a
much smaller n) is not. Aggregating the data relative to all
COPD subjects, we still observed a significant correlation
between PGE2 concentrations and the number of neutrophils
(
  0.5; P  0.004) in induced sputum samples (Fig. 2). We
also carried out the analysis of the correlation between PGE2
and neutrophils in the healthy smokers group or between PGE2
and macrophages in the healthy smokers or COPD subjects and
did not find any statistically significant correlation (P  0.1).
Effect of induced sputum supernatant and PGE2 on neutro-
phil adhesion. Based on the direct correlation between PGE2
concentrations and the percentage of neutrophils in induced spu-
tum, we evaluated the effect of supernatants of induced sputum
samples obtained from COPD subjects on the adhesion of periph-
eral blood neutrophils to human airway epithelial cells (16HBE).
Samples from six COPD smokers showing the highest concen-
trations of PGE2 (2 ng/ml, 0.6 nM) and six COPD former
smokers with lowest concentrations of PGE2 (1 ng/ml) were
used. The results obtained showed a significantly higher number
of adhering neutrophils on incubation with induced sputum su-
pernatants from COPD smoker subjects compared with samples
obtained from COPD former smoker subjects (P  0.001). Se-
lective immunoprecipitation of PGE2 from the same samples
significantly reduced neutrophil adhesion induced by supernatants
from COPD smokers but was basically ineffective on the activity
of supernatants from COPD former smokers (Fig. 3), suggesting
that PGE2 contributes to the increased adhesivity of neutrophils
incubated with supernatants from induced sputum from active
smoker COPD subjects.
Stimulation of AM from BAL and neutrophils from periph-
eral blood. AM and neutrophils from normal subjects when
pretreated with CSE (10%) significantly increased COX-2
expression and activity (as assessed by the production of PGE2
after activation with the calcium ionophore A23187). In par-
ticular, AM increased COX activity (Fig. 4A) and COX-2
expression (Fig. 4, C and E), reaching the maximum after 24 h
of incubation, and neutrophils increased their COX activity
(Fig. 4B) and COX-2 expression (Fig. 4, D and F), reaching a
maximum after 3 h of incubation with CSE, whereas at 24 h it
Fig. 4. COX activity and COX-1 and
COX-2 expression in alveolar macrophages
(AM) and neutrophils treated with cigarette
smoke extract (CSE). AM (A) and neutro-
phils (B) from normal donors were treated
with CSE (10%) for different times (0–24
h), challenged with 2.5 M calcium iono-
phore A23187 for 5 min, and analyzed for
PGE2 production as described in MATERIALS
AND METHODS. The cell lysates of AM stim-
ulated for 24 h with 10% CSE (C and E) and
of neutrophils stimulated for 3 h with 10%
CSE (D and F) were analyzed for COX-1
and COX-2 expression using specific West-
ern blots. Representative immunoblots are
shown in C and D. Quantitative densitomet-
ric results are reported in E and F as
means 	 SE (n  3) of the ratio vs. -actin.
PGE2 concentrations are expressed as
means 	 SD. Statistical analysis was per-
formed using ANOVA with Fisher protected
least significant differences correction for
multiple comparisons. *P 0.05 and **P
0.01 vs. Control.
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was possible to observe a decrease in COX activity. Similarly,
pretreatment with CSE markedly increased the expression of
EP2 and EP4 receptors in neutrophils, an effect that was
maximal at 3 h for EP2 receptors (Fig. 5, A and C) but still
remained quite significant at 24 h for both receptors (Fig. 5, B
and C). EP1 and EP3 receptor expression was not affected by
treatment with CSE (Fig. 5, A–C). These results were con-
firmed by quantitative RT-PCR analysis that showed increased
amounts of EP2 and EP4 mRNA (as indicated by the lower
number of amplification cycles required) after treatment with
CSE, whereas EP1 and EP3 did not change in response to CSE
(Fig. 6).
Effect of PGE2 on neutrophil adhesion. To confirm the
potential involvement of PGE2 in the enhanced adhesivity of
neutrophils observed in induced sputum samples, we tested the
effect of PGE2 on the adhesivity of CSE-treated, purified
peripheral blood neutrophils, showing a significant enhance-
ment at 1 and 10 nM but not at 100 nM (Fig. 7A). The EP2
receptor agonist Butaprost also significantly enhanced the ad-
hesivity of neutrophils to human airway epithelial cells,
whereas the effect of PGE2 was significantly blunted by the
preincubation of neutrophils with the EP4-selective antagonist
AH-23848 (30 M) (Fig. 7B). Pretreatment with a potent and
selective TP receptor antagonist (GR-32191B, 100 nM) did not
affect the enhanced adhesion induced by PGE2 (Fig. 7B). Neither
AH-23848 nor GR-32191B affected the adhesion of neutrophils
observed in the absence of PGE2 activation (Fig. 7B).
DISCUSSION
The present work provides evidence about a possible role of
COX-2 and its metabolite PGE2 on the neutrophil infiltration in
COPD subjects and suggests that cigarette smoke may signif-
icantly affect the contribution of PGE2 through the increased
expression of both its biosynthetic enzyme and specific recep-
tors in AM and/or neutrophils.
Induced sputum represents a well-accepted, minimally inva-
sive approach to the sampling of the airways of normal as well
as pathological subjects (21) and has been widely used in
COPD patients (38). The concentrations of PGE2, the main
proinflammatory COX metabolite, in induced sputum samples
from different group of subjects showed maximal values for
COPD current smoker subjects, followed by the group of
healthy smokers, whereas COPD former smoker had values
that were not higher than normal subjects. A similar pattern,
with increased expression in smokers (either healthy or COPD
Fig. 5. E-prostanoid EP1, EP2, EP3, and EP4 receptor expres-
sion in peripheral blood neutrophils treated with CSE. Neutro-
phils from normal donors were stimulated with CSE (10%) for
3 or 24 h. The total cell lysates were analyzed for EP1, EP2,
EP3, and EP4 expression using specific Western blots. Repre-
sentative immunoblots are shown in A and B. Quantitative
densitometric results are reported in C as means 	 SE (n  3)
of the ratio vs. -actin. *P  0.05 vs. the relevant Control.
Fig. 6. Real-time quantitative RT-PCR of EP1, EP2, EP3, and EP4 receptors
was performed in neutrophils treated with and without CSE (10%). Gene
expression levels are expressed as CT (crossover cycle at the threshold of PCR
amplification; the higher the number of cycles required to reach the CT, the
lower the abundance of target mRNA in the reaction). The results represent the
means	 SD of 3 different experiments performed with freshly purified normal
human neutrophils. *P  0.05 and **P  0.01 vs. Control.
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subjects), emerged looking at the expression of COX-2 in cells
obtained from induced sputum samples, although in this case
COPD former smoker subjects also were clearly distinguish-
able from controls. Although it appears clear that smoke per se
is able to induce COX-2 (and boost PGE2 production), irre-
spectively from the development of COPD, the finding that
COPD former smokers appear to have enhanced COX-2 ex-
pression is suggestive that long-lasting changes in the inflam-
matory status of airway cells are taking place specifically in
COPD subjects, and COX-2 may represent an important con-
tributor. Interestingly, PGE2 concentrations correlated with the
number of neutrophils present in induced sputum samples,
suggesting a potential causal relationship between the inflam-
matory mediator and the inflammatory cell influx within the
airways of COPD subjects. Indeed, preincubating normal pe-
ripheral blood neutrophils with the supernatant obtained from
induced sputum of current smoker COPD subjects resulted in
increased neutrophil adhesion to a human airway epithelial cell
line, compared with the effect of supernatant from COPD
former smoker subjects, characterized by lower concentrations
of PGE2. Neutrophil accumulation in the lung is a prominent
feature of COPD, and the activation of these cells, producing
proteases and oxygen-derived free radicals, is thought to be
important in the pathogenesis of the disease (41). A critical
passage is represented by the in situ formation of signal(s),
which may cause the influx and trapping of neutrophils within
the airways. Several factors have been considered for this role,
including lipid mediators such as leukotriene B4 and chemo-
kines such as IL-8, and it is quite reasonable that the system
may present significant redundancies, as cigarette smoke itself
is able to increase neutrophil adhesion (32).
PGE2 has been previously measured in exhaled breath con-
densate from exsmoker COPD subjects showing increased
concentrations compared with controls (18) and resistance to
treatment with COX-2-selective inhibitors (19), suggesting that
PGE2 in breath condensate may not be the result of COX-2
activity. Nevertheless, as the subjects participating in that study
were all former smokers, this appears to be consistent with our
data. The results of a very recent study carried out using
induced sputum samples supported the role of COX-2-derived
PGE2 in airway inflammation, suggesting it may contribute to
the severity of airflow limitation mediated by matrix metallo-
proteinase-2 (MMP-2) during progression of COPD (4). Inter-
estingly, increased concentrations of the urinary metabolite of
PGE2 have been reported in smokers and former smokers
compared with never-smoker subjects; in these subjects, treat-
ment with celecoxib, a selective COX-2 inhibitor, caused a
50% decrease in the excretion of urinary PGE2 metabolites,
providing evidence for a critical involvement of COX-2 in the
increased formation of PGE2 in smokers (6).
Cigarette smoke represents the most important risk factor in
the development of COPD given the compelling evidence that
smoke represents a significant source of oxidant species (5),
oxidative stress (17), and that the unbalance of oxidant and
antioxidant within the lung has been long linked to COPD (27).
Nevertheless, cigarette smoke is also known to induce the
expression of COX-2, as well as downstream isomerases, in
several cell types present within the airways (13, 39), and
indeed in our experimental conditions CSE was able to induce
COX activity, evaluated as maximal PGE2 biosynthesis and
COX-2 protein expression in both AM obtained from BAL of
control subjects and peripheral blood neutrophils. This is well
in agreement with the enhanced expression of COX-2 in
induced sputum cells as well as with the concentrations of
PGE2 that we observed in induced sputum supernatants ob-
tained from COPD and healthy smokers.
It is known that the activity of PGE2 is mediated by four
subtypes of EP receptors (EP1-4; Ref. 22). Interestingly, CSE
also significantly increased the expression of EP2 and EP4
receptors in purified human neutrophils, although leaving EP1
and EP3 receptors unaffected, as evaluated both by Western
blot analysis and quantitative RT-PCR. Although the role of
Fig. 7. Effect of PGE2 on neutrophil adhesion on pretreatment with CSE. Purified peripheral blood neutrophils were treated for 24 h with CSE (10%) and then
stimulated on human airway epithelial cells (16HBE) with different concentrations of PGE2 (A), the EP2-selective agonist Butaprost (100 nM), the selective EP4
antagonist AH-23848 (30 M), the potent and selective TxA2-PGH2 (TP) receptor antagonist GR-32191B (100 nM), and PGE2 (10 nM) in the presence or
absence of AH-23848 or GR-32191B (B). Adhesion was assessed by fluorescence measurements using a Wallac 1420 Victor multilabel counter (PerkinElmer)
as described in MATERIALS AND METHODS. Results are expressed as means	 SD of percentage of fluorescence. *P 0.05 vs. Control; #P 0.05 vs. 10 nM PGE2.
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each receptor has not been clearly established, an altered
expression of EP2 and EP4 receptors was observed in cells
from patients with asthma, supporting the hypothesis that these
receptors may be involved in chronic airway inflammation
(43). The activation of EP2 and EP4 receptors has mostly been
described as leading to a decreased adhesion/chemotaxis of
neutrophils (1, 2), but several differences can be noted between
previous publications and the conditions used in the present
study, namely: 1) higher PGE2 concentrations (100 nM)
and/or the concomitant use of phosphodiesterase inhibitors
were commonly used; 2) in most cases, the studied effect was
the inhibition of FMLP-induced neutrophil adhesion on pre-
treatment with PGE2; and 3) no pretreatment with CSE was
present. It is interesting to note that the common use of
phosphodiesterase inhibitors seems to link the inhibitory effect
on neutrophils to increased cAMP concentrations (7), whereas
the effects observed in the present study may involve alterna-
tive signal transduction mechanisms. In our work, we could
verify that low nanomolar (1–10 but not 100 nM) concentra-
tions of PGE2 were able to significantly enhance the adhesion
of CSE-treated neutrophils to airway epithelial cells, an effect
that was mimicked by the EP2-selective agonist Butaprost and
blunted by the EP4-selective antagonist AH-23848, suggesting
that both subtypes could play a role in the observed effect of
PGE2. The potential activity of PGE2 onto the TP receptor was
ruled out through the use of a specific antagonist. Previous
works reported about the activation of neutrophil by PGE2 (34)
or neutrophil-like HL-60 possibly through a cAMP-indepen-
dent mechanism (42), suggesting that the complex activities of
PGE2 within the context of the inflammatory reaction need
additional investigation, in particular with respect to the air-
ways. Indeed, evidence of possible anti-inflammatory activities
of PGE2 in the lung have been made available throughout the
years, and the bronchoconstriction observed on treatment with
COX inhibitors in aspirin-sensitive asthmatics (35) is clearly
pointing to a protective role of PGE2 in these subjects (29).
Interestingly, selective COX-2 inhibitors such as rofecoxib
appeared to be well-tolerated in these patients (14, 31), sug-
gesting that COX-1 may be responsible for the biosynthesis of
bronchoprotective PGE2.
In conclusion, we found increased PGE2 concentrations in
induced sputum from healthy and COPD smokers that, in
COPD subjects, correlated with the number of infiltrating
neutrophils. Based on this correlation, we were able to observe
a previously undescribed effect of COX-2-derived PGE2
within the airways, namely its ability to increase the adhesion
of neutrophils to human airway epithelial cells. CSE were
shown to induce both COX-2 and specific EP receptor subtypes
in AM and/or neutrophils, suggesting that smoking may play a
causal role also with respect to the observed effects of COX-
2-derived PGE2 within the airways of COPD subjects. Addi-
tional work is required to clarify the transduction mechanisms
involved in the observed effect of PGE2 on neutrophils.
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